BIOMAT Database Logo BIOMAT Database Logo

The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/- pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments. 2012

Dolores Serrano, and Susana Torrado, and Santiago Torrado-Santiago, and Javier P Gisbert
Department of Pharmaceutical Technology, Faculty of Pharmacy, Complutense University, Madrid, Spain.

Proton pump inhibitors (PPIs) are the most potent acid suppressants available. PPIs undergo hepatic metabolism via the CYP2C system for the isoforms CYP2C19 and CYP3A4 in particular. Genetic polymorphisms in CYP2C19 may affect the metabolism of individual PPIs to different extents. Although PPIs are highly effective as a class, differences in their pharmacokinetics, such as bioavailability and metabolism, may translate into differences in clinical outcomes. In Helicobacter pylori infection, a significantly lower eradication rate was seen in extensive metabolizers with omeprazole but no with rabeprazole.

UI MeSH Term Description Entries
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001189 Aryl Hydrocarbon Hydroxylases A large group of cytochrome P-450 (heme-thiolate) monooxygenases that complex with NAD(P)H-FLAVIN OXIDOREDUCTASE in numerous mixed-function oxidations of aromatic compounds. They catalyze hydroxylation of a broad spectrum of substrates and are important in the metabolism of steroids, drugs, and toxins such as PHENOBARBITAL, carcinogens, and insecticides. Microsomal Monooxygenases,Xenobiotic Monooxygenases,Hydroxylases, Aryl Hydrocarbon,Monooxygenases, Microsomal,Monooxygenases, Xenobiotic
D016480 Helicobacter pylori A spiral bacterium active as a human gastric pathogen. It is a gram-negative, urease-positive, curved or slightly spiral organism initially isolated in 1982 from patients with lesions of gastritis or peptic ulcers in Western Australia. Helicobacter pylori was originally classified in the genus CAMPYLOBACTER, but RNA sequencing, cellular fatty acid profiles, growth patterns, and other taxonomic characteristics indicate that the micro-organism should be included in the genus HELICOBACTER. It has been officially transferred to Helicobacter gen. nov. (see Int J Syst Bacteriol 1989 Oct;39(4):297-405). Campylobacter pylori,Campylobacter pylori subsp. pylori,Campylobacter pyloridis,Helicobacter nemestrinae
D016481 Helicobacter Infections Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease. Infections, Helicobacter,Helicobacter Infection,Infection, Helicobacter
D054328 Proton Pump Inhibitors Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX. Proton Pump Inhibitor,Inhibitor, Proton Pump,Inhibitors, Proton Pump,Pump Inhibitor, Proton
D065731 Cytochrome P-450 CYP2C19 A cytochrome P-450 enzyme subtype that oxidizes several important groups of drugs including many PROTON PUMP INHIBITORS and ANTICONVULSANTS. CYP2C19,CYPIIC19,S-Mephenytoin 4'-Hydroxylase,4'-Hydroxylase, S-Mephenytoin,CYP2C19, Cytochrome P-450,Cytochrome P 450 CYP2C19,P-450 CYP2C19, Cytochrome,S Mephenytoin 4' Hydroxylase

Related Publications

Dolores Serrano, and Susana Torrado, and Santiago Torrado-Santiago, and Javier P Gisbert
CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.
January 2010, Expert opinion on drug metabolism & toxicology,
Dolores Serrano, and Susana Torrado, and Santiago Torrado-Santiago, and Javier P Gisbert
Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole.
July 2012, Journal of clinical pharmacology,
Dolores Serrano, and Susana Torrado, and Santiago Torrado-Santiago, and Javier P Gisbert
Impact of the CYP2C19*17 polymorphism on the pharmacokinetics and pharmacodynamics of proton pump inhibitors.
March 2013, Journal of clinical pharmacology,
Dolores Serrano, and Susana Torrado, and Santiago Torrado-Santiago, and Javier P Gisbert
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
June 2005, Drug metabolism and pharmacokinetics,
Dolores Serrano, and Susana Torrado, and Santiago Torrado-Santiago, and Javier P Gisbert
Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori.
March 2003, Methods and findings in experimental and clinical pharmacology,
Dolores Serrano, and Susana Torrado, and Santiago Torrado-Santiago, and Javier P Gisbert
Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication.
March 2010, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology,
Dolores Serrano, and Susana Torrado, and Santiago Torrado-Santiago, and Javier P Gisbert
Can Helicobacter pylori be eradicated with high-dose proton pump inhibitor in extensive metabolizers with the CYP2C19 genotypic polymorphism?
May 2016, European review for medical and pharmacological sciences,
Dolores Serrano, and Susana Torrado, and Santiago Torrado-Santiago, and Javier P Gisbert
Influence of proton pump inhibitor treatment on Helicobacter pylori stool antigen test.
January 2012, World journal of gastroenterology,
Dolores Serrano, and Susana Torrado, and Santiago Torrado-Santiago, and Javier P Gisbert
Influence of a proton pump inhibitor-based therapy on Helicobacter pylori strain selection.
July 1997, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
Dolores Serrano, and Susana Torrado, and Santiago Torrado-Santiago, and Javier P Gisbert
Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
December 2008, Helicobacter,
Copied contents to your clipboard!